Immersive neurotechnology accountability doctrine

Introduction

The immersive neurotechnology accountability doctrine is a proposed legal framework for determining responsibility when immersive technologies interact directly with the human nervous system and influence perception, cognition, emotions, memory, or behaviour. It covers technologies such as brain-computer interfaces (BCIs), virtual-reality systems integrated with neural sensors, neurofeedback devices, and experimental systems capable of stimulating or interpreting brain activity.

Unlike conventional digital technologies, immersive neurotechnology may affect not only what a person sees or hears but also how that person experiences reality and makes decisions. These capabilities raise important questions concerning informed consent, mental privacy, bodily autonomy, product safety, data protection, and civil liability.

The doctrine is not currently a universally recognised, standalone legal doctrine. It is a proposed analytical framework developed from existing principles of constitutional law, medical ethics, product liability, privacy law, and emerging neurotechnology governance.

Meaning and scope of accountability

Accountability means that developers, manufacturers, healthcare providers, operators, and institutions must explain and justify their decisions, prevent foreseeable harm, and provide remedies when legal duties are breached.

The doctrine applies to several categories of immersive neurotechnology:

Neural monitoring: Systems that collect information about brain activity, attention, emotional responses, or cognitive states.

Neural stimulation: Devices that influence nervous-system activity for therapeutic or other purposes.

Immersive environments: Virtual or augmented reality systems combined with neurological monitoring or stimulation.

Adaptive neurotechnology: Systems that change their responses according to inferred mental states.

Brain-computer interfaces: Technologies that translate neural signals into commands or other outputs.

The degree of accountability should correspond to the level of risk. A non-invasive entertainment device that merely tracks head movement raises different concerns from an implanted neural interface that stimulates brain activity or processes highly sensitive neurological information.

Legal foundations of the doctrine

1. Human dignity and mental autonomy

Human dignity and autonomy require individuals to retain meaningful control over decisions affecting their bodies and minds. Immersive neurotechnology must not undermine this control through undisclosed stimulation, manipulative interfaces, or misleading representations of its capabilities.

In India, Article 21 of the Constitution protects life and personal liberty. Its interpretation includes important principles of dignity, privacy, and personal autonomy.

In Justice K.S. Puttaswamy (Retd.) v. Union of India (2017), the Supreme Court of India recognised privacy as a fundamental right. The judgment provides a strong constitutional foundation for protecting sensitive neural information and personal autonomy, although it did not specifically decide the regulation of neurotechnology.

2. Informed consent

Informed consent is essential where a neurotechnology system collects sensitive neural data, administers stimulation, or is used for medical treatment. Consent should explain the device's purpose, known risks, uncertainties, data practices, and available alternatives.

Consent should be voluntary, understandable, and sufficiently specific. A general acceptance of lengthy digital terms should not automatically be treated as informed consent to materially different neurological interventions.

In Samira Kohli v. Dr. Prabha Manchanda (2008), the Supreme Court of India explained the importance of informed consent in medical treatment. The decision is relevant by analogy to medical neurotechnology, particularly where an intervention exceeds the scope of consent originally provided.

3. Privacy and neural data protection

Neural data may reveal or permit inferences about health conditions, attention, emotional reactions, or other aspects of a person's mental life. Its collection and processing therefore require careful safeguards.

Accountability should require organisations to:

Collect only data necessary for a legitimate and disclosed purpose.

Explain whether neural information is stored locally or transmitted to external servers.

Restrict secondary use, profiling, and commercial disclosure.

Apply appropriate encryption, access controls, and retention limits.

Provide legally appropriate rights of access, correction, and deletion.

Assess risks arising from inaccurate or speculative inferences about mental states.

India's Digital Personal Data Protection Act, 2023, provides a general framework for digital personal data, subject to its scope, commencement, and applicable rules. Neural data that identifies or relates to an identifiable individual may fall within that framework. The Act does not, however, establish a complete, specialised regime for neural information.

Case laws and judicial principles

1. Justice K.S. Puttaswamy v. Union of India (2017)

The Supreme Court of India recognised privacy as a fundamental right under the Constitution. The judgment connected privacy with dignity, autonomy, and the ability to make personal choices.

Relevance: This case supports constitutional scrutiny of intrusive neural-data collection and technologies that threaten personal autonomy. It does not establish a specific neural-rights doctrine, but its privacy principles are highly relevant to developing one.

2. Samira Kohli v. Dr. Prabha Manchanda (2008)

The Supreme Court of India addressed informed consent in medical treatment and distinguished valid consent from consent that does not adequately cover the intervention performed.

Relevance: Medical neurotechnology developers and practitioners should ensure that individuals understand material risks and the nature of proposed neurological interventions. The case is an established medical-consent authority, although it did not concern brain-computer interfaces.

3. Montgomery v. Lanarkshire Health Board [2015] UKSC 11

The UK Supreme Court held that medical professionals must take reasonable care to ensure that patients are aware of material risks and reasonable alternatives to proposed treatment.

Relevance: This judgment supports a patient-centred approach to risk disclosure for clinical neurotechnology. Information about uncertain neurological effects, alternative treatments, and limitations may be material to a person's decision.

4. Airedale NHS Trust v. Bland [1993] AC 789

The House of Lords considered the legal principles governing the withdrawal of life-sustaining treatment in a patient in a persistent vegetative state.

Relevance: The decision illustrates the complexity of legal responsibility when medical technology intersects with consciousness, bodily integrity, and patient interests. It is not a direct authority on immersive neurotechnology, and its relevance is limited to broader questions of medical decision-making and legal responsibility.

5. Moore v. Regents of the University of California (1990)

The Supreme Court of California considered a patient's claims arising from the use of biological materials obtained during medical treatment for research and commercial purposes.

Relevance: The case highlights issues involving disclosure, consent, and the commercial use of human biological material. By analogy, it raises questions about the use of neural signals and derived information for research or commercial development. It does not establish that neural data is legally equivalent to biological tissue or that every neural-data use creates a property right.

Allocation of legal responsibility

A workable accountability doctrine must identify which parties are responsible for different risks.

Responsibility should depend on the party's role, control over the risk, applicable legal duties, and contribution to the harm. A manufacturer should not automatically be liable for every adverse outcome, nor should a user be expected to bear all responsibility for risks concealed by a developer.

Proposed regulatory framework

The following measures could operationalise the doctrine.

Risk classification: Regulators should distinguish low-risk immersive devices from systems capable of clinical intervention, neural stimulation, or sensitive mental-state inference. Higher-risk systems should require stronger evidence of safety and effectiveness.

Pre-market assessment: High-risk medical devices should undergo applicable regulatory review, clinical evaluation, and risk management. In India, the Medical Devices Rules, 2017, and the applicable framework administered by the Central Drugs Standard Control Organisation may be relevant, depending on the product's intended purpose and classification.

Continuous monitoring: Manufacturers and operators should maintain incident-reporting mechanisms, investigate adverse effects, issue safety notices, and provide updates where necessary. Significant software changes should receive additional assessment where they alter neurological or clinical risks.

Neural-data governance: Organisations should establish clear limits on collection, retention, disclosure, and secondary use. Particularly sensitive processing should receive enhanced scrutiny, with safeguards against unauthorised profiling and discriminatory use.

Independent oversight: High-risk research should receive appropriate ethics review, while commercial systems should be subject to proportionate regulatory audits and documented risk assessments.

Effective remedies: People affected by unsafe or unlawful systems should have access to complaint mechanisms and any applicable remedies under consumer-protection, medical-negligence, product-liability, data-protection, or constitutional law.

Challenges in implementation

The doctrine faces several difficulties. First, the relationship between a device and a person's psychological or behavioural response may be scientifically uncertain. Second, multiple parties may contribute to a single harmful outcome, making causation difficult to establish. Third, rapid software updates may change system behaviour after the initial assessment. Fourth, neural information may be difficult to anonymise reliably when combined with other datasets.

Cross-border regulation presents another challenge because a device may be developed in one country, hosted on servers in another, and used by individuals elsewhere. International cooperation and compatible safety standards would help reduce regulatory gaps.

The law must also avoid treating every influence on attention or emotion as unlawful. The central questions should be whether the technology creates a material risk, violates a recognised legal duty, interferes unlawfully with protected rights, or causes legally actionable harm.

Conclusion

The immersive neurotechnology accountability doctrine offers a structured approach to governing technologies that interact directly with human cognition and neurological activity. Its foundation lies in established principles of privacy, dignity, informed consent, medical responsibility, product safety, and data protection.

Cases such as Puttaswamy, Samira Kohli, and Montgomery provide relevant legal foundations, but none establishes a comprehensive doctrine specifically for immersive neurotechnology. The framework should therefore be understood as a proposed legal model, implemented through existing laws and supplemented by targeted legislation where necessary.

Ultimately, effective accountability requires risk-based regulation, transparent consent, secure handling of neural data, clearly allocated responsibilities, and accessible remedies for people harmed by unsafe or unlawful systems.